8-K/A
filed April 4, 2023, 7:59 PM ET
CIK 0001780097
M&A
confidence high
sentiment negative
materiality 0.90
Baudax Bio, Inc.: M&A transaction — Baudax Bio transfers ANJESO assets to Alkermes, terminates related agreements, amends credit facility
Baudax Bio, Inc.
- Transferred patents, trademarks, equipment, data, and ANJESO NDA to Alkermes; no further payments due under terminated ANJESO agreements.
- Amended credit agreement: lenders consented to asset sale, released liens on transferred assets, reduced minimum liquidity covenant to $2.5M.
- Issued warrants to MAM Eagle Lender for 785,026 shares at $1.8951/share, exercisable for 10 years; registration rights granted.
- Company will withdraw ANJESO NDA and transfer to Alkermes if requested; acquired regulatory approvals included in transfer.
Key facts
Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
Baudax Bio, Inc. amended credit facility with Wilmington Trust, National Association.
- Instrument
- credit facility
- Counterparty
- Wilmington Trust, National Association
- Event
- amendment
Exact text from the filing
LLC, Baudax Bio Limited, Wilmington Trust, National Association, solely in its capacity as administrative and collateral agent and the lenders party and (ii) the Company entered into an Asset Transfer Agreement with Alkermes Pharma Ireland Limited (the “Transfer Agreement”), each as described in greater detail in the Original 8-K.
View on SEC.gov
M&A Transactions
SEC 8-K Item 2.01/5.01
confidence 0.9
Baudax Bio, Inc. completed a disposition involving Alkermes Pharma Ireland Limited (closed 2023-03-29).
- Action
- disposition
- Counterparty
- Alkermes Pharma Ireland Limited
- Closing
- 2023-03-29
Exact text from the filing
LLC, Baudax Bio Limited, Wilmington Trust, National Association, solely in its capacity as administrative and collateral agent and the lenders party and (ii) the Company entered into an Asset Transfer Agreement with Alkermes Pharma Ireland Limited (the “Transfer Agreement”), each as described in greater detail in the Original 8-K.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.95
Baudax Bio, Inc. amended Amendment No. 5 and Consent to Credit Agreement with Wilmington Trust, National Association, as agent, and the lenders party thereto (effective 2023-03-29).
- Action
- amendment
- Agreement
- credit facility
- Counterparty
- Wilmington Trust, National Association, as agent, and the lenders party thereto
- Effective
- 2023-03-29
Exact text from the filing
On March 29, 2023 (the “Closing Date”), Baudax Bio, Inc. (the “Company”) entered into that certain Amendment No. 5 and Consent to Credit Agreement (the “Amendment”) by and among the Company, Baudax Bio N.A. LLC (“Baudax LLC”), Baudax Bio Limited, Wilmington Trust, National Association, solely in its capacity as administrative and collateral agent (the “Agent”) and the lenders party thereto (the “Lenders”).
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Baudax Bio, Inc. terminated ANJESO Agreements (PSA, ATLA, Manufacturing Agreement) with Alkermes Pharma Ireland Limited (effective 2023-03-29).
- Action
- termination
- Agreement
- supply
- Counterparty
- Alkermes Pharma Ireland Limited
- Effective
- 2023-03-29
Exact text from the filing
Alkermes Agreement On March 29, 2023, the Company entered into an Asset Transfer Agreement with Alkermes Pharma Ireland Limited (“Alkermes”) (the “Transfer Agreement”). Under the terms of the Transfer Agreement, the Company transferred the rights to certain patents, trademarks, equipment, data and other rights related to ANJESO ® (the “Assets”) to Alkermes.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.95
Baudax Bio, Inc. entered into Asset Transfer Agreement with Alkermes Pharma Ireland Limited (effective 2023-03-29).
- Action
- entry
- Agreement
- asset purchase
- Counterparty
- Alkermes Pharma Ireland Limited
- Effective
- 2023-03-29
Exact text from the filing
On March 29, 2023, the Company entered into an Asset Transfer Agreement with Alkermes Pharma Ireland Limited (“Alkermes”) (the “Transfer Agreement”).
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.8
Baudax Bio, Inc. entered into Registration Rights Agreement with MAM Eagle Lender, LLC (effective 2023-03-29).
- Action
- entry
- Counterparty
- MAM Eagle Lender, LLC
- Effective
- 2023-03-29
Exact text from the filing
the registration rights agreement by and between the Company and MAM Eagle Lender, LLC, entered into on March 29, 2023 (the “Registration Rights Agreement”).
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.